Clinical trial
EPO906 Therapy in Patients With Prostate Cancer
NCT00035113 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00035113 |
|---|---|
| Title | EPO906 Therapy in Patients With Prostate Cancer |
| Official title | An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Androgen-independent Prostate Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | epothilone b |
| Enrollment | 48 |
| Start date | Jan 1, 2002 |
| Primary completion | Jan 1, 2004 |
| Completion | Jan 1, 2004 |
| First posted | May 3, 2002 |
| Last update posted | Feb 9, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: